Zusammenfassung
Hintergrund
Komplexe Verläufe der Knochenheilungsstörung führen zu einer schweren wirtschaftlichen und sozialen Belastung des Patienten. Ziel dieser prospektiven Studie ist die Überprüfung des Therapieerfolgs nach der lokalen Applikation von „bone morphogenetic protein 7“ (BMP-7).
Material und Methode
Von 06/2002 bis 06/2008 wurden bei 98 Patienten 101 Operationen mit BMP-7 vorgenommen. Das Durchschnittsalter lag bei 50 (18–88) Jahren. Die Patienten waren zum Zeitpunkt der BMP-7-Applikation durchschnittlich 3,3-mal (Median 3; 1- bis 13-mal) voroperiert. Wir verwendeten BMP-7 im „off label use“ an allen langen Röhrenknochen.
Ergebnisse
In 93 Fällen (92%) fand eine Konsolidierung statt. Die mittlere Heilungsdauer betrug 4,8 (4; 1,5–11) Monate. BMP-7 wurde im Durchschnitt 18,4 (14; 3–84) Monate nach der Verletzung angewendet. In 65 Fällen erfolgte die BMP-7-Applikation mit Reosteosynthese und Spongiosaplastik. Ernsthafte Nebenwirkungen wurden nicht beobachtet.
Schlussfolgerung
BMP-7 zeigt gerade bei therapierefraktären Pseudarthrosen eine hohe Effektivität. Die Anwendung von BMP-7 bleibt jedoch eine Einzelfallentscheidung, wobei BMP-7 im klinischen Alltag nach kritischer individueller Indikationsstellung auch im „off label use“ eingesetzt werden kann.
Abstract
Background
Complex patterns of impaired bone healing can result in a severe economic and social burden for the patient. Herein we describe the local application of recombinant human bone morphogenetic protein 7 (BMP-7). The goal of this prospective study is to review the indications, application and validation of this therapy.
Material and method
From June 2002 to June 2008, we applied 101 BMP-7 treatments in 101 nonunions of 98 patients. The average age of the patients was 50 years (18–88 years). The gender composition was 29 women (30%) and 69 men (70%). Before BMP-7 application, patients had already underwent surgical treatement an average of 3.3 times (median 3, 1- to 13-times). We used BMP-7 “off-label” in all long bones.
Results
In 93 cases (92%), we observed proper bone healing. The average healing time was 4.8 months (range 1.5–11 months). The average time from injury to BMP-7 application was 18.4 months (3-84 months). In 65 cases, BMP-7 application was combined with re-osteosynthesis and autologous bone grafting. Serious side effects were not observed.
Conclusions
BMP-7 should not be used as general treatment of nonunion in all patients, but appears to be effective for the treatment of complex cases. In clinical practice, the decision to proceed with off-label use of BMP-7 should be made on a case-by-case basis.
Literatur
Zimmermann G, Henle P, Kusswetter M et al (2005) TGF-beta1 as a marker of delayed fracture healing. Bone 36:779–785
Moghaddam A, Weiss S, Wolfl CG et al (2010) Cigarette smoking decreases TGF-beta1 serum concentrations after long bone fracture. Injury 41(10):1020–1025
Moghaddam A, Muller U, Roth HJ et al (2010) TRACP 5b and CTX as osteological markers of delayed fracture healing. Injury 42(8):758–764
Moghaddam A, Zimmermann G, Hammer K et al (2011) Cigarette smoking influences the clinical and occupational outcome of patients with tibial shaft fractures. Injury doi:10.1016/j.injury.2011.05.011 (Epub ahead of print)
Einhorn TA (1998) The cell and molecular biology of fracture healing. Clin Orthop Relat Res 355(Suppl):7–21
Bhandari M, Guyatt G, Tornetta P 3rd et al (2008) Randomized trial of reamed and unreamed intramedullary nailing of tibial shaft fractures. J Bone Joint Surg Am 90:2567–2578
Schmidmaier G, Schwabe P, Wildemann B, Haas NP (2007) Use of bone morphogenetic proteins for treatment of non-unions and future perspectives. Injury 38(Suppl 4):35–41
Giannoudis PV, Einhorn TA, Schmidmaier G, Marsh D (2008) The diamond concept–open questions. Injury 39(Suppl 2):5–8
Zimmermann G, Moghaddam A, Reumann M et al (2007) TGF-beta1 as a pathophysiological factor in fracture healing. Unfallchirurg 110:130–136
Gaston MS, Simpson AH (2007) Inhibition of fracture healing. J Bone Joint Surg Br 89:1553–1560
McKibbin B (1978) The biology of fracture healing on long bones. J Bone Joint Surgery 60B:150–162
Tonnensen PA, Heerfordt J, Pers M (1975) 150 open fractures of the tibial shaft: The relation between necrosis of the skin and delayed union. Acta Orthop Scand 46:823–835
Macey LR, Kana SM, Jingushi S et al (1989) Defects of early fracture healing in experimental diabetes. J Bone Joint Surg Am 71:722–733
Cruess RL, Sakai T (1972) The effect of cortisone upon synthesis rates of some components of rat bone matrix. Clin Orthop Rel Res 86:253–259
Rankin EA, Metz JCW (1970) Management of delayed union in early weight bearing treatment of the fractured tibia. J Trauma 10:751–759
Sarmiento A, Schaeffer JF, Beckerman L et al (1977) Fracture healing in rat femora as affected by functional weight bearing. J Bone Joint Surg Am 59:369–375
Hayda RA, Brighton CT, Esterhai JL (1998) Pathophysiology of delayed healing. Clin Orthop Rel Res 355:31–40
Giannoudis PV, Psarakis S, Kanakaris NK, Pape HC (2007) Biological enhancement of bone healing with Bone Morphogenetic Protein-7 at the clinical setting of pelvic girdle non-unions. Injury 38(Suppl 4):43–48
Giannoudis PV, Tzioupis C, Green J (2009) Surgical techniques: how I do it? The Reamer/Irrigator/Aspirator (RIA) system. Injury 40:1231–1236
Hakimi M, Jungbluth P, Thelen S et al (2010) Platelet-rich plasma combined with autologous cancellous bone: An alternative therapy for persistent non-union? Unfallchirurg 113:788
Masquelet AC, Begue T (2010) The concept of induced membrane for reconstruction of long bone defects. Orthop Clin North Am 41:27–37
Jingushi S, Mizuno K, Matsushita T, Itoman M (2007) Low-intensity pulsed ultrasound treatment for postoperative delayed union or nonunion of long bone fractures. J Orthop Sci 12:35–41
Zimmermann G, Muller U, Loffler C et al (2007) Therapeutic outcome in tibial pseudarthrosis: Bone morphogenetic protein 7 (BMP-7) versus autologous bone grafting for tibial fractures. Unfallchirurg 110:931–938
Seiler JG 3rd, Johnson J (2000) Iliac crest autogenous bone grafting: donor site complications. J South Orthop Assoc 9:91–97
Giannoudis PV, Kanakaris NK, Dimitriou R et al (2009) The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions. Clin Orthop Relat Res 467:3239–3248
Giannoudis PV, Tzioupis C (2005) Clinical applications of BMP-7: the UK perspective. Injury 36(Suppl 3):47–50
Moghaddam A, Elleser C, Biglari B et al (2010) Clinical application of BMP 7 in long bone non-unions. Arch Orthop Trauma Surg 130:71–76
Zimmermann G, Moghaddam A, Wagner C et al (2006) Clinical experience with bone morphogenetic protein 7 (BMP 7) in nonunions of long bones. Unfallchirurg 109:528–537
Urist MR, Strates BS (1971) Bone morphogenetic protein. J Dent Res 50:1392–1406
Friedlaender GE, Perry CR, Cole JD et al (2001) Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83(Suppl 1):151–158
Haag I (2011) Off-Label-Use von Arzneimitteln im Krankenhaus. das Krankenhaus 103
Ellert U, Kurth BM (2004) Methodological views on the SF-36 summary scores based on the adult German population. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:1027–1032
Dimitriou R, Dahabreh Z, Katsoulis E et al (2005) Application of recombinant BMP-7 on persistent upper and lower limb non-unions. Injury 36(Suppl 4):51–59
Wagner FMM, Bühren V (2010) Ergebnisse der Anwendung von Bone Morphogenic Proteine 7 (Osigraft) als Behandlungsbestandteil in der rekonstruktiven Chirurgie: eine Fallserie von 213 konsekutiven Behandlungen [online]. Available at: http://www.egms.de/static/de/meetings/dkou2009/09dkou310.shtml
Giannoudis PV, Dinopoulos HT (2010) BMPs: Options, indications, and effectiveness. J Orthop Trauma 24(Suppl 1):9–16
Goldhahn J, Mitlak B, Aspenberg P (2008) Critical issues in translational and clinical research for the study of new technologies to enhance bone repair. J Bone Joint Surg Am 90(Suppl 1):43–47
Giannoudis PV, MacDonald DA, Matthews SJ et al (2000) Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br 82:655–658
Axelrad TW, Einhorn TA (2009) Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev 20:481–488
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moghaddam-Alvandi, A., Zimmermann, G., Büchler, A. et al. Ergebnisse der Pseudarthrosenbehandlung mit „bone morphogenetic protein 7“ (BMP-7). Unfallchirurg 115, 518–526 (2012). https://doi.org/10.1007/s00113-011-2100-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00113-011-2100-0